DPA-714 PET
Phase 1Small molecule
DPA-714 PET is one of 4 small molecule programs targeting SARS-CoV-2. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in SARS-Cov-2
#DrugCompanyPhaseTrials
1Veklury
GileadPreclinical
DPA-714-PET/MRI
UUniversity of Alabama at Birmingham
Phase 1
DPA-714 PET
UUniversity Hospital, Tours
Phase 1
SARS-Cov-2 Virus 1x10^2 TCID50
IImperial College London
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cognitive Decline1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DPA-714 PET. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity Hospital, Tours